Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical-stage biopharmaceutical company developing a portfolio of potent new antibiotics designed to be effective against dangerous, drug-resistant bacteria, today announced presentations at two upcoming investor conferences. The Company’s lead antibiotic candidate, eravacycline, is currently in Phase 3 development for use as a potential first-line monotherapy for the treatment of multidrug-resistant (MDR) infections, including those caused by many of the MDR Gram-negative bacteria highlighted as urgent public health threats by the Centers for Disease Control and Prevention (CDC).
Help employers find you! Check out all the jobs and post your resume.
